Home The Word Brain	My Amedeo FAQ Privacy About
	C49 In our changing world, speaking just English isn't enough. Open new doors with skills in another world language. Start with 7 words a day. Next week: +49.

Genetics

Free Subscription Articles published in J Natl Cancer Inst Retrieve available abstracts of 14 articles: HTML format

Single Articles

April 2025
1. DEBORTOLI E, McGahan E, Yanes T, Berkman J, et al
   Utility of genomic testing in children, adolescents, and young adults with cancer.
   J Natl Cancer Inst. 2025;117:601-610.
   PubMed     Abstract available
   
   
   January 2025
2. STACKLAND S, Schnabel D, Dinan MA, Presley CJ, et al
   Strength of evidence underlying the CMS-FDA parallel review of comprehensive genomic profiling tests in the cancer setting.
   J Natl Cancer Inst. 2025;117:144-151.
   PubMed     Abstract available
   
   
   
3. GOGLIA AG, Alshalalfa M, Khan A, Isakov DR, et al
   Pan-cancer genomic analysis reveals FOXA1 amplification is associated with adverse outcomes in non-small cell lung, prostate, and breast cancers.
   J Natl Cancer Inst. 2025;117:188-197.
   PubMed     Abstract available
   
   
   December 2024
4. DAS D, Wang X, Chiu YC, Bouamar H, et al
   Integrative multi-omics characterization of hepatocellular carcinoma in Hispanic patients.
   J Natl Cancer Inst. 2024;116:1961-1978.
   PubMed     Abstract available
   
   
   November 2024
5. MIRZA MB, Choi J, Marincola Smith P, Baechle JJ, et al
   ERBB2 amplification in gastric cancer: a genomic insight into ethnic disparities.
   J Natl Cancer Inst. 2024;116:1830-1833.
   PubMed     Abstract available
   
   
   September 2024
6. KEANE F, Chou JF, Walch H, Schoenfeld J, et al
   Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated disease.
   J Natl Cancer Inst. 2024;116:1429-1438.
   PubMed     Abstract available
   
   
   August 2024
7. ZHANG X, Zhao L, Ngo LH, Dillon ST, et al
   Prediagnostic plasma proteomics profile for hepatocellular carcinoma.
   J Natl Cancer Inst. 2024;116:1343-1355.
   PubMed     Abstract available
   
   
   May 2024
8. JONES CM, Karp J, Davis DS
   Genomic testing and patient rights.
   J Natl Cancer Inst. 2024;116:771-772.
   PubMed    
   
   
   April 2024
9. SUN J, Luo J, Jiang F, Zhao J, et al
   Exploring the cross-cancer effect of circulating proteins and discovering potential intervention targets for 13 site-specific cancers.
   J Natl Cancer Inst. 2024;116:565-573.
   PubMed     Abstract available
   
   
   February 2024
10. BASU A, Rais-Bahrami S
    Genomic risk scores in prostate cancer: polygenic yes, but are they poly-ancestral?
    J Natl Cancer Inst. 2024 Feb 16:djae025. doi: 10.1093.
    PubMed    
    
    
    
11. MEERNIK C, Raveendran Y, Kolarova M, Rahman F, et al
    Racial and ethnic disparities in genomic testing among lung cancer patients: a systematic review.
    J Natl Cancer Inst. 2024 Feb 6:djae026. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2023
12. HUEY RW, Shah AT, Reddi HV, Dasari P, et al
    Feasibility and value of genomic profiling in cancer of unknown primary: real-world evidence from prospective profiling study.
    J Natl Cancer Inst. 2023;115:994-997.
    PubMed     Abstract available
    
    
    
13. WANG H, Ding XH, Liu CL, Xiao Y, et al
    Genomic alterations impacting tumor-infiltrating lymphocytes and PD-L1 expression patterns in triple-negative breast cancer.
    J Natl Cancer Inst. 2023 Aug 7:djad154. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2023
14. FENG X, Wu WY, Onwuka JU, Haider Z, et al
    Lung cancer risk discrimination of prediagnostic proteomics measurements compared with existing prediction tools.
    J Natl Cancer Inst. 2023 Jun 1:djad071. doi: 10.1093.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Genetics is free of charge.